ReviewCurrent oncology reports2014
Revisiting oxaliplatin-based regimens for advanced hepatocellular carcinoma.
Review in Current oncology reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- SPOP-mediated K27-linked non-degradative ubiquitination of KCNN3 suppressing HCC progression via the CTCF-SATB1 axis.Cell death & disease · 2026Article
- Activation of mechanosensitive ion channel Piezo1 linking metabolic reprogramming and pro-inflammatory responses in hepatocellular carcinoma.Cell communication and signaling : CCS · 2025Article
- AdipoR1 enhances the radiation resistance via ESR1/CCNB1IP1/cyclin B1 pathway in hepatocellular carcinoma cells.Molecular medicine (Cambridge, Mass.) · 2025Article
- Inhibition of pyruvate dehydrogenase kinase‑1 by dicoumarol enhances the sensitivity of hepatocellular carcinoma cells to oxaliplatin via metabolic reprogramming.International journal of oncology · 2020Article
- CCN2-MAPK-Id-1 loop feedback amplification is involved in maintaining stemness in oxaliplatin-resistant hepatocellular carcinoma.Hepatology international · 2019Article
- CRKII overexpression promotes theOncology letters · 2019Article
- Curative effect of endostar combined with oxaliplatin in the treatment of primary hepatic carcinoma and its influence on immune cells.Oncology letters · 2019Article
- The NKD1/Rac1 feedback loop regulates the invasion and migration ability of hepatocarcinoma cells.Scientific reports · 2016Article
- β-elemene sensitizes hepatocellular carcinoma cells to oxaliplatin by preventing oxaliplatin-induced degradation of copper transporter 1.Scientific reports · 2016Article
- Overexpression of SASH1 Inhibits the Proliferation, Invasion, and EMT in Hepatocarcinoma Cells.Oncology research · 2016Article
- Association between MTHFR A1298C polymorphism and hepatocellular carcinoma risk.International journal of clinical and experimental medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is a global health problem, as it is the sixth most common cancer in the world and the third leading cause of cancer-related death. Many patients with HCC present with disease that is not suitable for any potentially curative therapy; such patients are candidates for palliative transarterial or systemic therapies. Sorafenib is the only systemic therapy to demonstrate modest survival benefit over supportive care in the context of randomised controlled trials. However, many cytotoxic chemotherapeutics have achieved a range of tumour responses, but so far without convincing survival benefits in smaller phase II studies. In this commentary, we will review the data regarding the recent interest for the use of oxaliplatin-based regimens for advanced HCC.
Indexed as
Identifiers
24867344What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.